Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

(NASDAQ:MLYS) RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How does this offering compare to recent capital raises by comparable biotech peers in terms of size, pricing, and market reception? What are the intended uses for the offering proceeds and how will they impact the company's clinical development timeline? How will the $175 million equity raise affect Mineralys Therapeutics' share dilution and valuation?
Symbol: MLYS
Equity offering
12 days ago
Read more globenewswire

NYSE American to Commence Delisting Proceedings Against Spirit Aviation Holdings, Inc. (FLYY)

(FLYY) NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common...

What is the expected timeline for the delisting process and any potential re‑listing or reverse‑strike actions by the company? What are the short‑term trading opportunities or risks (e.g., potential OTC trading, pink sheet listing) following the NYSE American delisting? How will the immediate delisting suspension affect FLYY's liquidity and price volatility?
Symbol: FLYY
Delisting
12 days ago
Read more businesswire

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

(NASDAQ:CGTX) PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat ...

Who are the two new fundamental institutional investors and does their participation signal increased credibility for Cognition’s pipeline? What are the expected timelines and milestones for Phase 3 of Zervimesine (CT1812) and how might they impact the stock? How will the $30 million capital raise affect dilution and future earnings per share?
Symbol: CGTX
Financing
12 days ago
Read more globenewswire